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ABSTRACT
Initiation of gene transcription by transcription fac-
tors (TFs) is an important regulatory step in many
developmental processes. The differentiation of T cell
progenitors in the thymus is tightly controlled by signal-
ing molecules, ultimately activating nuclear TFs that reg-
ulate the expression of T lineage-specific genes. During
the last 2 years, significant progress has been made in our
understanding of the signaling routes and TFs operating
during the earliest stages of thymic differentiation at the
CD4–CD8– double negative stage. Here we will review the
TF families that play an important role in differentiation
of thymocytes, particularly focusing on recent new infor-
mation with respect to the Tcf, bHLH, GATA, and
CBF/HES TF families. Stem Cells 2001;19:165-179
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INTRODUCTION
Regulation of gene expression, establishing cell- or dif-
ferentiation stage-specific gene expression profiles, occurs
at multiple levels. These include opening of a locus for the
transcriptional machinery, initiation of RNA transcription
by transcription factors (TFs) that attract the RNA poly-
merase II complex, RNA splicing, transport of transcripts
out of the nucleus, mRNA stability, and in a broad sense,
translation and post-translational modifications of the gene
products (proteins) such as (de)phosphorylation and glyco-
sylation [1]. Initiation of transcription is probably the most
important regulatory step in control of gene expression.
TFs, proteins that bind to specific DNA sequences present
in the core promoters and enhancers of genes, are important
in the initiation of gene-specific transcription. Before they
can exert their action, initiation of transcription is control-
led by more global mechanisms that regulate accessibility
of a locus. This level of regulation is mediated by changes
in chromatin structure through changes in histone acetyla-
tion of nucleosomal DNA and demethylation of CpG dinu-
cleotides. In addition to decondensation of chromatin,
silencers and locus control regions regulate global changes
in gene expression [1].
Recent evidence has shown that this strict separation
between specific TFs and factors that regulate locus accessi-
bility is an oversimplified model. Certain TFs also attract
factors that mediate (de)acetylation of histones thereby 
regulating chromatin remodeling [2-5].
Most of the TFs we now know to be important for T
cell differentiation were identified by promoter/enhancer
studies of T cell-specific genes, such as the CD3 and T cell
receptor (TCR) genes. Others were originally found in B
cells, but turned out to play pivotal roles in T cell develop-
ment as well. Since TFs do not function in isolation, much
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attention has recently been devoted to the interaction with
other proteins and the signaling routes controlling TFs dur-
ing development. For instance, we now know about the
importance of the balance in expression levels of E2A TFs
and their dominant-negative interacting partners, the Ids.
We have learned that Tcf/Lef TFs are the downstream effec-
tors of the evolutionary conserved Wnt pathway. Studies of
the Notch pathway, a signaling pathway critically important
at many stages of T cell differentiation, have revealed a
whole new class of TFs, the CBF and HES families, that are
likely to be important for T cell development. We will sys-
tematically discuss these different factors here focusing on
more recent discoveries, after we have given a short
overview of the different stages of T cell differentiation in
the thymus. For extensive descriptions of the discovery of
these TFs, expression pattern and phenotype of the null-
mutant mice that were generated, the reader is referred to
any of the many reviews that were published recently [6-10].
STAGES OF T CELL DIFFERENTIATION
T cells develop from common lymphoid progenitor cells
that seed the thymus from the fetal liver or bone marrow [11].
T cells differentiating in the thymus are phenotypically dis-
tinguished by the expression of CD4 and CD8 co-receptors;
T cells are either double negative (DN), double positive (DP),
or single positive (SP) for these two cell-surface antigens
(Fig. 1). During the DN stage T cells can be subdivided into
four distinct subsets (DN1-4), based on rearrangement of
their TCR genes and the expression of surface antigens. In
the mouse these antigens are CD44 and CD25 in the fol-
lowing order: CD44+CD25– (DN1), CD44+CD25+ (DN2),
CD44–CD25+ (DN3), and CD44–CD25– (DN4).
T cells rearrange their TCRD locus in the DN1 stage and
the TCRG locus in the DN2 stage [12]. During the transition
to the next stage of T cell maturation, the pre-T cell stage
(DN3), the cells shut down proliferation [13] and TCRβ genes
begin to rearrange. During the immature single positive (ISP)
stage the rearranged TCRβ is expressed at the cell surface
complexed to pre-Tα as the pre-TCR-complex. In the mouse
these ISP cells express CD8, while in humans they express
CD4. In both species, the ISP cells represent a stage of rapid
proliferation, driven by signals emanating from pre-TCR. The
resultant DP cells comprise 85%-90% of an adult thymus and,
after rearranging their TCRA locus, undergo positive (for
recognition of self-major histocompatibility) and negative
(against autoreactivity) selection. DP cells which fail to
receive the TCR-mediated signal within 3-4 days will enter
the apoptotic pathway, while selected cells develop into CD4
or CD8 SP cells that have high CD3/TCR expression. These
cells exit the thymus and become circulating T cells that
reside in blood and peripheral lymphoid organs.
Ikaros and Related TFs
Ikaros is a member of a family of lymphoid-restricted
zinc-finger TFs including Helios and Aiolos [14-16].
Through alternative splicing at least six different isoforms
are produced, some of which (forms 4-6) lack one or more
of the four zinc-fingers responsible for DNA binding [14,
17]. These forms probably function as naturally occurring
dominant-negative forms.
The first attempts to produce Ikaros null-mutant mice gen-
erated mice lacking the DNA-binding zinc fingers 1-3, which
resulted in a stable dominant-negative form of Ikaros (as was
later shown) that can dimerize with other Ikaros-related pro-
teins, such as Aiolos, but cannot bind DNA [18]. These mice
lack all T, B, and natural killer (NK) cells and their progeni-
tors, suggesting that Ikaros-related proteins are required for
survival or development of common lymphoid stem cells.
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Figure 1. T cell differentiation in the thymus. Depicted are the different stages in both human and mouse T cell development, indicating the surface markers
of subpopulations and rearranagement of the TCR genes. Although different markers are used for the subpopulations in mouse and humans, the basic mech-
anisms are conserved. This figure has been designed to emphasize similarities rather than differences between species.
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Later on true Ikaros-null mice were produced by delet-
ing the last coding exon, which contains the transactivation
and dimerization domain [19]. In these mice B cell devel-
opment is blocked, as initially is the case for T cell devel-
opment. During fetal life, thymocytes are absent, but 5 days
after birth they start to appear, and after a few weeks a thy-
mus with normal cellularity has developed. However, there
are fewer CD8+ SP cells, and γδ T cell development is
affected. Mature T cells show hyperproliferation after TCR
engagement [19]. A more detailed analysis revealed that
DN1 and DN3 cells were decreased, but DN4 cells were
not, suggesting that Ikaros members influence β-selection
via the pre-TCR [20].
Several studies have shown that Ikaros, and its T cell-
specific family member Aiolos, exert at least some of their
function as transcriptional repressors. Ikaros proteins were
shown to associate with heterochromatin in interphase
nuclei, a region associated with transcriptionally silent genes
[21, 22]. In T cells, Helios/Ikaros complexes were shown to
associate with centromeric clusters, where transcriptionally
silent genes are located. When thymocytes are not in cell
cycle, or when mature T cells remain resting, no centromeric
clustering of Ikaros protein was observed, but in cycling cells
such clusters were readily observed. This suggests that Ikaros
proteins keep genes silent by repositioning these genes to
heterochromatin. Unfortunately, these studies did not inves-
tigate which forms of Ikaros (for instance the forms lacking
zinc fingers) were present in these clusters.
GATA-3
GATA-3 was originally identified as a protein that
binds to the TCRα gene enhancer [23]. GATA-3 is a mem-
ber of a family of TFs that bind the GATA-consensus motif
(T/A)GATA(A/G) through a highly conserved C-terminal 
C4 zinc finger binding domain [24]. The GATA family con-
tains six members, two of which, GATA-1 and GATA-2, are
expressed in various hematopoietic lineages. In contrast,
GATA-4, -5, and -6 are expressed in developing cardiac
structures, in the gut, the urogenital system, smooth muscle
cells, and in the brain. GATA-3 expression is abundant in the
developing central nervous system, adrenal gland and kidney.
Within the hematopoietic system GATA-3 expression is
confined to T lymphocytes and NK cells [23, 25-28]. GATA-
3 is expressed in early steps of mouse hematopoietic develop-
ment, in the intraembryonic regions known to give rise to
hematopoietic precursors [29]. When GATA-3 expression was
evaluated in various hematopoietic progenitors purified by
flow cytometry, expression was observed in hematopoietic
stem cells, common lymphoid progenitors, pro-T and pre-T
cells, but not in progenitors of the granulocyte/macrophage or
megakaryocyte/erythrocyte lineage or in pro- or pre-B cells
[30]. The GATA-3 gene is already expressed in the earliest
CD25–CD44+ DN progenitors in day 12 fetal thymus [31].
Using mice with an insertion of a lacZ reporter in the GATA-
3 gene on one allele (GATA-3+/nlslacZ), the proportion of
GATA-3-expressing cells was quantified during T cell devel-
opment [25]. GATA-3 expression was significant at the DN1
stage in the thymus. The two waves of TCRβ and TCRα gene
recombination were associated with low proportions of
GATA-3+ cells. The stage of rapidly proliferating DN4 and
ISP cells, which insulates these two periods of TCR rearrange-
ment, was characterized by a large proportion of GATA-3-
expressing cells [25]. The proportion of GATA-3+ cells, which
was low in DP cells, increased with the onset of positive
selection events, characterized by CD3 and TCRαβ upregula-
tion and CD69 expression, and reached its highest level at the
CD4+CD8lowCD69+ stage at which the T cells make the
CD4/CD8 lineage commitment decision (R.W.H., unpub-
lished results). GATA-3 expression remained high during the
maturation of CD4 SP cells in the thymus, but is downregu-
lated after commitment to the CD8 lineage, and is finally
completely lost in mature CD8+ cells in the periphery [25].
Mice with a targeted deletion of GATA-3 die between
embryonic day 11 and 12, displaying massive internal bleeding,
central nervous defects, and growth retardation [28]. Recently,
it was reported that noradrenaline deficiency of the sympathetic
nervous system is a major cause of the embryonic lethality [32].
Pharmalogical rescue of GATA-3–/– fetuses beyond day 11 by
feeding catechol intermediates to pregnant females revealed
various abnormalities later in fetal development, including
severe thymic hypoplasia at fetal day 16.5 [32].
Antisense GATA-3 oligonucleotides inhibited T cell
development from fetal liver precursors in fetal thymic organ
cultures (FTOC), indicating the critical importance of GATA-
3 for early T cell development [31]. Moreover, RAG-2–/–
complementation experiments in vivo demonstrated that the
development of GATA-3–/– embryonic stem (ES) cell-derived
T cell precursors is arrested at or before the DN stage [33]. In
such GATA-3–/–/RAG-2–/– chimeric mice, the thymus con-
tained only DN cells, in which the presence of GATA-3–/– ES
cell-derived thymocytes could not be detected. In contrast, the
GATA-3-deficient ES cells contributed significantly to non-
hematopoietic tissues and the erythroid, myeloid, and B cell
lineages. In chimeric mice generated by injection of GATA-
3-deficient lacZ-expressing ES cells in wild-type blastocysts,
it was shown that GATA-3–/– ES cells did not contribute to the
T cell lineage, not even to the earliest subset of CD25–CD44+
DN thymic progenitors [25]. Although GATA-3 activity
could be required for the proliferation or survival of cells
within this earliest DN cell population in the thymus, it seems
more likely that GATA-3 is essential for the development
of T-lineage-restricted progenitors in fetal liver and bone
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marrow. This would be supported by the observed expression
of GATA-3 in common lymphoid progenitors [30] and the
inhibition of in vitro T cell development from fetal liver pre-
cursors by antisense oligonucleotides [31]. Taken together,
these findings demonstrate an essential role for GATA-3 in 
T cell commitment, comparable to the role of the TF Pax-5 in
B cell development [34].
The presence of GATA-3-binding sites has been
described in the TCRα, TCRβ, TCRδ, and CD8α enhancers,
and binding of GATA-3 to these enhancers induced their
activity [23, 35, 36], suggesting a role for GATA-3 in the
regulation of TCR rearrangement or TCR transcription. The
highest level of GATA-3 transcription was observed in the
stage of rapidly dividing DN3 cells, which have passed 
β-selection, as well as in the DP cells during the positive
selection phase [25]. In this context, the function of GATA-
3 might well parallel its function in the regulation of the
Th2 cytokine locus, where GATA-3 acts by inducing chro-
matin remodeling during cellular proliferation. Alterna-
tively, GATA-3 might be involved in the induction of
cellular proliferation after the successful completion of
TCR rearrangments. This hypothesis would be supported
by findings for other GATA family members that implicate
them in cell fate decisions by the induction of proliferation
at the expense of differentiative potential [25].
Basic Helix-Loop-Helix Proteins, Especially E-Box Proteins
Basic helix-loop-helix (bHLH) proteins have been impli-
cated in gene regulation during differentiation processes of
many distinct cell types, including lymphoid cells.
The basic domain of the bHLH proteins is involved in
DNA binding, whereas dimerization is mediated via the
two helices separated by a loop. As dimerization is a pre-
requisite for proper DNA binding, the exact function of
bHLH factors is dependent on their dimerization pattern.
The bHLH TFs can be subdivided into several classes,
based on their structure, dimerization potential, and/or
function (Table 1) [37]. Class I proteins, also known as 
E-box binding proteins or E proteins for their capacity to
bind to E-box sequences (CANNTG) within regulatory ele-
ments, comprise E2A (or better its E47 and E12 splice
forms), HEB, and E2-2, and also the Drosophila daughter-
less protein. These E proteins are able to form homodimers,
but can also heterodimerize with the tissue-specific class II
bHLH proteins, examples of which include MyoD, Myf5,
and, for example, the human and mammalian homologues
of the Drosophila protein achaete-scute (HASH, MASH).
The class III proteins, of which c-Myc is the best studied
example, contain a zip domain in addition to the bHLH
domain and can form heterodimers with class IV bHLH-zip
proteins like Mad and Max. The Id (inhibitor of DNA bind-
ing) proteins forming class V lack a basic DNA-binding
domain, but can still heterodimerize with E proteins,
thereby inhibiting proper binding of these factors to their
target sequences. The class VI proteins are recognized on
the basis of a Pro residue in the basic region; the HES-1
protein that functions downstream of Notch is an example
of this type. Finally, class VII proteins, of which AHR is an
example, contain a bHLH domain as well as a PAS domain.
Insight into the role of bHLH proteins in lymphoid and
more specific T cell differentiation has largely come from
studies on mice deficient in the E proteins E2A and HEB,
and from transgenic mice overexpressing Id proteins, that
act as inhibitors of E proteins. Collectively, these studies
provide evidence that, contrary to, for example, myogene-
sis, E proteins themselves are the major bHLH factors reg-
ulating lymphoid differentiation and that tissue-specific
(class II) bHLH TFs do not seem be involved. E2A-defi-
cient mice display a complete block in B cell differentiation
around the pro-B cell stage, prior to the occurrence of
immunoglobulin (Ig) DH-JH rearrangements [38]. In addi-
tion to the B cell phenotype, E2A–/– mice also exhibit a pro-
found, though less severe, defect in T cell differentiation.
On average these mice have fivefold fewer thymocytes,
with a decrease in especially the CD4+/CD8+ DP thymocyte
population and a concomitant small increase in the CD4+
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Table 1. Classification of bHLH proteins
Class Features Examples
Class I E proteins, which can homodimerize or heterodimerize with class II proteins E2A, E2-2, HEB, da
Class II tissue-specific bHLH proteins, which heterodimerize with class I proteins MyoD, Myf 5, MASH, HASH, TAL1, as-c
Class III bHLH-zip proteins c-Myc, TFE3
Class IV bHLH-zip proteins which heterodimerize with class III proteins Max, Mad
Class V HLH proteins without basic domain, which heterodimerize with class I proteins, Id1, Id2, Id3, Id4, emc
thereby inhibiting class I DNA binding
Class VI bHLH proteins with Pro residue in basic region HES-1, hairy/enhancer of split
Class VII bHLH-PAS proteins AHR
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and especially the CD8+ SP cell populations [39]. The
decrease in DP cells is due to a partial block in one of the ear-
liest stages of thymocyte differentiation, the DN1 stage [39].
HEB–/– mice also display a partial block in T cell dif-
ferentiation next to a clear B cell differentiation defect [40].
This partial block in HEB-deficient mice is at the transition
from DN to DP cells, which occurs later than in E2A-defi-
cient mice [41]. Importantly, mice expressing a dominant-
negative HEB protein show an earlier block at the DN stage
[42]. The latter observation points towards an important role
for E2A-HEB heterodimers in regulating differentiation
processes in T cells, next to E2A and HEB homodimers.
Indeed E47-HEB dimers have been observed as predominant
complexes in T cells [39, 43], although detectable levels of
both homodimers have also been found. Apparently, there is
some level of redundancy between E proteins in T cells, and
presumably not in B cells in which only high levels of pre-
dominantly E47 homodimers are found. This would then
explain the remarkable difference in severity of the E2A
defect for B- and T-lymphoid differentiation, in that a lack of
E2A TFs in E2A-null mice can partially be compensated for
by HEB proteins in differentiating T cells, but not B cells.
The third E protein, E2-2, has not been studied exten-
sively in lymphoid cells. However, mice with a targeted dele-
tion of the E2-2 gene do not exhibit a clear T cell phenotype,
despite expression of E2-2 mRNA in thymocytes; this is in
contrast to its presumed role in B cell differentiation, given
the effect of E2-2 inactivation on the B cell phenotype [40].
Another series of studies stressing the central role of E
proteins in differentiation of lymphocytes are those on trans-
genic mice constitutively expressing Id proteins, as well as
studies in which FTOC are retrovirally transduced with Id
proteins. Overexpression of the Id1 gene in mice results in
impaired B cell differentiation at a stage similar to the block
in E2A–/– mice [44], whereas the observed T cell phenotype of
these mice with many DN cells resulted from massive apop-
tosis of differentiating T cells rather than a developmental
block [45]. Transgenic mice overexpressing the Id2 HLH pro-
tein display a stage-dependent differentiation block with a sig-
nificant increase in CD4–CD8+ ISP cells [46]. The constitutive
Id2 level in these mice overrules normal Id2 downregulation
at the ISP stage, thereby keeping E2A and HEB bound, result-
ing in a differentiation block and an increased proliferation at
the stage with TCRβ-chain rearrangements. Alternatively, the
excess free Id2 levels per se might induce proliferation and
block differentiation. The role of Id3 in thymocyte differenti-
ation has been studied quite extensively. Retroviral transduc-
tion of human CD34+CD1a– progenitor cells with an Id3
encoding retrovirus was found to inhibit TCRαβ T cell dif-
ferentiation, but instead was found to promote the develop-
ment of NK cells [47]. Transduction with Id3 of CD4+ ISP
cells that are already committed to the T cell lineage showed
that TCRαβ but not TCRγδ T cell differentiation is severely
disrupted [48]. In line with these findings, Id2–/– mice lack
lymph nodes and show a greatly reduced population of NK
cells [49]. Studies on Id3–/– mice illustrate that Id3 is required
for positive selection in thymocytes and that negative selection
is severely perturbed when Id3 is lacking, thus identifying Id3
as an essential component for proper thymocyte differentiation
[50]. Overall, data from the various studies on the role of Id
HLH proteins suggest the importance throughout thymocyte
differentiation of a delicate balance in the levels of E proteins
E2A and HEB on the one hand and Id factors on the other.
Further evidence for the importance of E proteins in lym-
phoid differentiation comes from a completely different set of
observations. In human T cell acute lymphoblastic leukemias
(T-ALL), several different chromosome aberrations are
found in which class II bHLH TFs are involved. These
include a microdeletion on chromosome 1p32 harboring the
TAL1 or SCL gene [51], and translocations t(1;7)(p32;q35)
and t(1;14)(p32;q11) both involving TAL1 [52, 53],
t(7;9)(q35;q32) involving TAL2 [54], t(7;19)(q35;p13)
involving LYL1 [55], and t(14;21)(q11;q22) involving
BHLHB1 [56]. As a result of all these aberrations, the involved
bHLH genes will be juxtaposed to TCR gene regulatory ele-
ments and subsequently activated. Inappropriate expression
may then lead to leukemic transformation in thymocytes, pos-
sibly (partly) through functional inactivation of E proteins such
as E2A and HEB that are required for proper thymocyte
development. Oligomeric TF complexes in erythroid cells
containing TAL1-E2A heterodimers as well as LMO1 and
LMO2 proteins [57] illustrate the in vivo complexing potential
of these factors. Moreover, TAL1 in concert with LMO1 can
repress the transactivation potential of E2A proteins [58-60].
Further support for the E protein inactivation hypothesis
comes from a recent study where aberrant expression of TAL1
and LMO1 in double transgenic mice leads to inactivation of
E2A-HEB function, influences HEB-induced pre-TCRα (pre-
Tα) chain expression, and alters thymocyte differentiation
[61]. Consistent with this idea is the rapid development of lym-
phomas of immature T cell phenotype in E2A–/– mice as well
as Id1 and Id2 transgenic mice [39, 45, 46].
Together, all these data point towards a pivotal role for E
proteins in lymphoid and especially T cell differentiation.
Disruption of E2A and HEB through targeted deletion of the
E proteins or functional inactivation via binding to constitu-
tively expressed dominant-negative Id proteins or tissue-spe-
cific bHLH factors, as in human T cell leukemias, might block
their function as key regulators in thymocyte differentiation. In
addition, this inactivation model also predicts a block in the
presumed tumor-suppressor function of E2A, resulting in the
development of lymphomas.
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Originally, the E proteins have been identified as tran-
scriptional regulators binding to IGH and IGK enhancer
sequences [62]. Within these enhancers several E-box
sequences can be discerned that act as the actual binding sites
for E proteins. Full enhancer activity is required for tran-
scription and recombination of Ig genes, suggesting that E
proteins play an essential role in these processes. E2A is
required for proper regulation of many B-lineage-specific
genes, including RAG1, RAG2, λ5, VpreB, EBF, and PAX-5
[63-66]. Analogous to Ig enhancers, E-box-binding sites have
also been recognized in enhancers of the TCRδ/TCRα locus as
well as the TCRβ locus, suggesting a role for E proteins in reg-
ulation of TCR recombination similar to Ig rearrangement
[67]. The observation that particular subsets of TCRγδ cells are
lacking in E2A–/– mice is in support of this idea; such E2A-reg-
ulated differential accessibility to the recombination enzymes
seems to be E2A dosage-dependent [68].
Further evidence comes from experiments using human
kidney cells, in which TCRG (Vγ-Jγ) as well as only the
immature incomplete type of TCRD rearrangements (Dδ2-
Dδ3 and Vδ2-Dδ3) can be induced upon E2A or HEB intro-
duction in the presence of RAG activity (Langerak et al.,
submitted). The inability to detect Jδ1 rearrangements in this
system is in line with observations that in vitro E47 cannot
bind to the TCRD enhancer [69], which is thought to regulate
accessibility to the Jδ region. E47 is, however, able to bind
the TCRA enhancer, whereas transactivation of the endoge-
nous TCRA enhancer could be inhibited by the class II bHLH
factor TAL1 [69]. E2A-HEB heterodimers are also known to
interact with the CD4 enhancer and regulate its activity in T
cells [43]. Furthermore, in line with earlier described results,
thymic RAG activity was found to be several-fold lower in
E2A-deficient mice, suggestive of E protein-mediated regu-
lation of RAG genes in relation to TCR recombination in T
cells [70]. In addition to the above-described regulatory
effects of E proteins on rearrangement processes, E2A was
also suggested to be involved in growth regulation processes.
The finding that overexpression of E2A in NIH3T3 cells pro-
moted growth arrest could be explained by transcriptional
activation of the cyclin-dependent kinase inhibitor p21/CIP1
gene by E2A [71]. Enhanced expression of class I bHLH pro-
teins in 293T cells resulted in apoptosis induction leading to
a decreased proliferation rate [72]. Furthermore, expression of
Id proteins in fibroblasts induced cell cycle progression, most
probably through inhibition of E-box-binding proteins [73].
Inactivation of E2A leading to inhibition of cell cycle arrest
might thus well be (part of) the mechanism by which the dis-
ruption of the presumed tumor-suppressor effect of E2A and
subsequent transformation of lymphoid cells can occur.
As illustrated above, E proteins have thus been implicated
in regulating gene rearrangement and growth control processes
in lymphoid cells. An important question remaining is, which
mechanism or signaling event regulates E protein activity, or
better, the ratio between E-box stimulating activity and Id
inhibitory activity, in differentiating T cells. Although not
much is known about this type of regulation, one candidate
regulator might be the Notch protein, which is located in the
membrane but acts as transcriptional activator following pro-
teolytic cleavage. Notch signals seem to function via inhibition
of E2A-regulated promoters, whereas the phenotype of mice
overexpressing Notch-1 is similar to that of E2A-deficient
mice [74]. Notch activation via its downstream target HES-1,
which is a class VI bHLH factor, has been suggested to 
be required for T cell development, whereas in its absence
cells would choose a B cell fate [74]. In Hes-1–/– mice T cell
development is indeed arrested at the DN1 stage [75, 76].
Tcf/Lef Proteins
Tcf-1 is the prototypic member of a family of proteins
containing an HMG-box as the DNA-binding domain [77-
81]. These include Lef-1, Tcf-3, and Tcf-4. Lef-1 is present
not only in T cells but also in immature B cells [80], whereas
Tcf-1 is highly T cell-specific in adult mice. The functions
of Tcf-3 are not well characterized, whereas Tcf-4 plays a
vital role in maintenance of the stem cell compartment in the
gut [82]. Reconstitution of lethally irradiated mice with
Tcf4–/– fetal liver stem cells resulted in mice with normal 
T and B cell development, indicating that Tcf-4 is not
required for T (or B) cell development (Staal, O’Toole,
Meeldijk, Clevers, unpublished observations).
Two different Tcf-1 mutant mice have been generated
[83]. In Tcf(V) mutant mice, a low level of a truncated yet
functional Tcf-1 is still expressed, whereas the Tcf(VII) muta-
tion abolishes the DNA-binding activity of TCF-1 completely
and presumably induces a null-phenotype. Disruption of Tcf-1
in Tcf (VII) mutant mice results in a block in T cell develop-
ment at the ISP to DP transition [83] and within the DN com-
partment at the CD44+CD25– to CD44+CD25+ transition [84].
Importantly, cells in the DN2 and ISP stages are apparently
not proliferating [84]. Thymocyte development is not com-
pletely blocked because of the compensatory role of Lef-1.
Both Tcf-1 mutations have been crossed into the Lef-1
mutant mouse strain. Lef-1–/– mice have several develop-
mental defects, including a defect pro-B cell differentiation,
but develop to term and display normal thymocyte develop-
ment [85]. While Tcf (V) mutant mice are viable and have
modestly impaired thymocyte development, Lef-1/Tcf (V)
double-mutant mice display a complete block in thymocyte
development at the ISP stage [86]. Lef-1–/– Tcf (VII)–/– mice
die at E10 [87] with dramatic developmental defects affect-
ing the limb buds and neural tube. T cell development can
obviously not be studied in these embryos.
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Remarkably, in 4-6-month-old Tcf-1 null mice, thymo-
cyte development is completely blocked at the DN1 stage.
Moreover, Tcf-1 knockout (KO) bone marrow stem cells can
give rise to all hematopoietic lineages except T cells in radi-
ation chimeras ([84] and Staal, Meeldijk, and Clevers, unpub-
lished observations). Taken together, Tcf-1 is required for
the earliest stages of adult T cell development, but in fetal 
thymopoiesis its requirement is less stringent.
Tcf-1 is not an active TF by itself, but requires the interac-
tion with the Wnt effector β-catenin [88]. Until recently, it was
unknown which signal transduction routes control Tcf-depen-
dent transcription, but they are likely to act by ultimately pro-
viding β-catenin in the nucleus
to interact with its partner Tcf-1
to activate target genes. Signals
operating on DN thymocytes,
such as the preTCR and the
cytokines interleukin 7 (IL-7)
and stem cell factor, do not acti-
vate Tcf-dependent transcrip-
tion [89]. We now know that
Wnt signaling activates Tcf-
dependent transcription in
thymocytes. Thus, the signal-
ing route for a TF involved in
T-lymphoid development has
now been identified.
β-catenin is a known com-
ponent of the Wnt signaling
cascade [90]. Wnt proteins con-
stitute a large (>19 members)
family of extracellular signal-
ing molecules that are found in
many different species and
influence cell fate and cell
behavior during development.
Among the best-studied effects
of Wnt are the determination of
segment polarity in Drosophila
and the specification of the
body axis in Xenopus [90].
Deregulation of Wnt signaling has been shown to occur in sev-
eral human cancers through mutations in key molecules of the
Wnt pathway, including β-catenin [91, 92]. Wnt function as
ligands for members of the Frizzled (Fz) family of serpentine
receptors. Wnt binding to Fz initiates a complex signaling cas-
cade that culminates in nuclear translocation of β-catenin
(Fig. 2), that can then interact with members of the Tcf/Lef
family to activate transcription of target genes [91, 93, 94].
In the absence of Wnt signals, a negative regulatory
kinase, GSK3β, acts by inducing phosphorylation of β-
catenin [95] and its subsequent degradation via the ubiqui-
tin/proteasome pathway [96] (Fig. 2). Both β-catenin and
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Figure 2. Wnt signaling pathway.
Wnt binds to a Frizzled receptor
via a cysteine rich domain (CRD).
Soluble Frizzled receptors (some-
times referred to as Frzb) occur
that act as dominant negative mol-
ecules of Wnt signaling. In absence
of Wnt, β-catenin is phosphory-
lated by GSK3β or a related
kinase, leading to its ubiquitinylation and degradation. Tcf-1 is inactive, and bound by Grg repressors in the nucleus. Binding of Wnt to Fz lead to
inactivation of GSK3β via Dsh. β-catenin is not (hyper) phosphorylated and migrates to the nucleus, where it binds to Tcf-1 to activate target genes.
Wnt
CRD
CK-I
CK-II P
Dsh
?
P
GSK3β APC
Axin
β-catenin
β-catenin
Tcf-1
Tcf-1
Grg
†Degraded
β-catenin
PROTEASOME
P
P
β-catenin
Axin
APCGSK3β
Ubiquitin
Dsh
?
Frizzled
Wnt
CRD
CRD
Frzb
No Wnt signaling Active Wnt signaling
 by on November 27, 2006 www.StemCells.comDownloaded from 
GSK3β are present in a complex with axin and the adeno-
matous polyposis coli tumor-suppressor protein [97]. In the
absence of β-catenin in the nucleus, Tcf may recruit mem-
bers of the Grg/groucho family, which act as global repres-
sors of transcription [98]. Upon Wnt signaling, dishevelled
(Dsh) is activated via unknown mechanisms, possibly
involving phosphorylation via casein kinase I and II (CKI,
CKII) [99, 100]. Activated Dsh inactivates the activity of
GSK3β, leading to hypo- or dephosphorylation of β-catenin
and its subsequent accumulation and nuclear import. In most
reviews, this accumulation of β-catenin has been seen as
important for transducing Wnt signals [101]; however, recent
data suggest that it is not the high levels of β-catenin, but the
dephosphorylation of critical residues in its N-terminus that
regulate the signaling activity of β-catenin (Staal, van Noort,
and Clevers, manuscript in preparation). For instance, arti-
ficial accumulation of β-catenin via pharmacological inhi-
bition of its breakdown (a Wnt-independent way to increase
β-catenin levels) does not activate Tcf-dependent transcrip-
tion. Thus, there is no direct correlation between levels of
β-catenin and activation of the Wnt-responsive TF Tcf.
In certain cell types such as fibroblasts, inhibition of
GSK3β (for instance by treatment with lithium, a known
GSK3β inhibitor) is sufficient to activate transcription of Tcf
reporter genes, thereby mimicking Wnt signaling [89].
However, in T cells, inhibition of GSK3β is insufficient to
activate Tcf-dependent transcription [89]. Recent experiments
using highly sensitive reporter genes have, however, shown
that lithium can induce Tcf-dependent transcription in T cells,
but not as strongly as in fibroblasts (van Noort, Clevers,
unpublished observations). This suggests a difference in reg-
ulation of Wnt signaling between T lymphocytes and fibro-
blasts, perhaps because of differential regulation of GSK3β
activity or the involvement of another, not yet identified,
kinase in T cells.
A recent study has shown that Wnt can activate Tcf-con-
trolled transcription in thymocytes, and subsequently, that
Wnt signals are required for normal T cell development
[102]. Retroviral expression of soluble Wnt receptor mutants
that block Wnt signaling, in combination with FTOC,
showed that thymocyte differentiation was inhibited at the
DN to DP transition [102]. These results imply an important
role for the Wnt cascade in early thymocyte development.
Moreover, transduction of fetal thymocytes with Wnt1 and
Wnt4 resulted in increased survival or increased proliferation
in an in vitro cell culture system [102]. This shows that Wnt
signals are growth factors for pro- and pre-T cells.
Other studies have shown that Wnt signaling also func-
tions as a growth factor for hematopoietic stem cells [103] and
pro B cells [104], where Lef-1 is the Wnt-responsive TF. In
light of the redundancy between Tcf-1 and Lef-1 during T cell
development, we propose that both Tcf-1 and Lef-1 can serve
to transduce Wnt signals in developing thymocytes.
Another TF with an HMG box which is not part of the
TCF family, Sox 4, has been investigated. While these mice
mainly have cardiac and B cell developmental defects, they
have some problems in T cell development as well [105,
106]. FTOC with Sox4–/– thymi demonstrated an impaired
transition of DN to DP cells.
HES-1, CBF-1, and the Notch Signaling Pathway
As mentioned above, HES-1 is a TF of the class VI
bHLH family. HES-1 is expressed in both thymocytes and
thymic stromal cells [75], and its expression in thymocytes
is regulated by Notch signaling.
Notch was first identified in Drosophila as a gene that
plays a critical role in regulating cell fate decisions during
neuronal and epidermal cell differentiation [107]. In mam-
mals, four Notch homologs have been identified (Notch 1-4),
that function as receptors interacting with Notch ligands,
that are also transmembrane receptors of the so-called DSL
(Delta/Serrate/lag2) family and comprise Jagged1/Serrate1,
Jagged2/Serrate2, Delta1, Delta2, and Delta3 [108]. Interactions
between cells expressing Notch and cells expressing DSL lig-
ands result in proteolytic cleavage of Notch, releasing its
intracellular domain, that translocates to the nucleus and inter-
acts with the CBF-1/RBP-Jκ TF, converting it from a repres-
sor to an activator of gene transcription [109, 110] ( Fig. 3).
The targets of activated CBF1/RBP-Jκ are incompletely char-
acterized but include the hairy enhancer of split (HES) genes,
that are upregulated by Notch and in turn downregulate the
activity of certain bHLH TFs.
Recent data suggest that Notch signaling and HES-1 may
play a critical role in promoting progression through several
major checkpoints during T cell development, including the
choice of committing to the T cell rather than the B cell lin-
eage, the choice between the αβ and γδ lineages and, in the
case of αβ T cells, the choice between the CD4+ and CD8+
lineages [111].
Tomita and coworkers [75] found that transfer of HES-1–/–
fetal liver cells into RAG2–/– host mice normally reconstituted
B cells but failed to generate mature T cells in the thymus. In
the reconstituted thymus, T cell differentiation was arrested at
DN1 (partially) and the early DN3 stage. The cause of these
blocks is unknown, but is speculated to be due to a defect in
the proliferative expansion of DN1 and DN2 thymocytes [75].
Thymocytes in the HES-1–/– reconstituted mice express T cell
markers, which is in contrast to experiments with inducible
deletion of Notch-1. In these experiments the majority of the
DN1 cells in the thymus expressed markers of the B cell lin-
eage and phenotypically resembled immature bone marrow B
cells [112]. These results suggest that HES-1, in contrast to
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Notch signaling, does not
appear to play an obligatory
role in commitment to the T
cell lineage, and that other TFs
downstream of Notch are likely
to be involved in Notch-regu-
lated commitment.
Additional evidence for a
role for Notch in T cell lineage
commitment comes from
experiments in which bone marrow stem cells expressing
constitutively active Notch-1 were used to reconstitute irra-
diated hosts. In these mice differentiation of stem cells into
the B cell lineage was completely blocked and a thymus-
independent population of T cells developed in the bone mar-
row [74]. Thus, lymphoid precursor cells develop into T cells
via Notch signaling, but in the absence of such signals
choose a B cell fate. Notch signals may function by inhibit-
ing E2A activity, as Notch signals have been shown to block
activation of an E2A-regulated promoter via induction of
HES-1 [74, 113]. Indeed the phenotype of the E2A–/– mice is
very similar to the phenotype of mice derived by overex-
pression of activated Notch-1 in bone marrow precursors.
Furthermore, a role for Notch in T cell lineage develop-
ment is suggested by the finding that the Notch-1 gene is
involved in chromosomal translocations with the TCRβ gene
in a subset of cases of human T-ALL [114].
In addition to a role during the DN stage of T cell devel-
opment, it was proposed that HES-1 functions to regulate the
CD4+ versus CD8+ cell fate choice. The expression of CD4 is
developmentally regulated, in part, by a silencer element that
prevents its expression in DN and CD8+ SP thymocytes [115,
116]. HES-1 has been found to bind to this CD4 silencer in
vitro. In addition, overexpression of HES-1 inhibited tran-
scription from a reporter construct containing CD4 regulatory
elements and inhibited the expression of endogenous CD4 in
T cell clones [113]. However, the physiological significance of
these results is unclear. There was no difference in the level of
expression of HES-1 between CD4+ and CD8+ T cell clones,
and the binding of HES-1 to the CD4 silencer was detected in
T cell clones that express CD4, indicating that this may not be
a functionally significant interaction. The authors also men-
tioned that expression of HES-1 in transgenic mice does not
enhance CD8+ SP development. However, a role for Notch1
signaling in this binary cell fate decision is suggested by in
vivo results in which Notch1 transgenic expression influences
CD4 versus CD8 T cell fate [117].
While there is no experiment to support a role for HES-
1 in αβ versus γδ T cell lineage commitment, Notch signal-
ing has clearly been shown to be involved in this process.
This was first suggested by analysis of mice reconstituted
with a mixture of bone marrow stem cells derived from
Notch-1+/+ and Notch-1+/– mice [111]. Both subpopulations
contributed equally to the B cell lineage, however the
Notch-1+/– stem cells contributed less than the Notch-1+/+
stem cells to the αβ T cell lineage. Second, analysis of T
cell development in transgenic mice expressing constitu-
tively active Notch-1 showed that, although the number of
γδ T cells in these mice was normal, a higher percentage of
them expressed CD4 and CD8, markers usually found on
αβ T cells, and only rarely on γδ cells [111].
From the studies described above, we conclude that Notch
signaling has an essential role during several stages of T cell
development. Although HES-1 has been shown to be involved
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Figure 3. Notch signaling. The
Notch receptor is processed in the
Golgi by Furin and Fringe genes
and expressed at the plasma
membrane. Upon interaction with
ligand (Delta or Jagged), Notch is
cleaved by two different proteases
(ADAM family proteases and
Presenilin). The intracellular
domain of Notch migrates to the
nucleus via unknown mechanisms
and interacts with the CBF-1 TF.
The Notch-IC, CBF-1 complex
activates transcription of HES
genes and others.
CBF-1 *
HES-1
HES-5
Notch-1
Others
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in the maturation of DN thymocytes and the regulation of
CD4/CD8 lineage commitment, other TFs downstream of
Notch-1 remain to be identified.
Other TFs
Several other TFs that have fairly subtle effects on T
cell development in the thymus have been described. These
include TFs originally identified in the Il2 minimal pro-
moter such as the NF-κB/Rel factors and NF-AT, but also
other factors such as CREB.
The NF-κB TF family includes NF-κB1 (p50/p105), NF-
κB2 (p52/p100), RelA (p65), c-Rel, and RelB. These TFs play
important roles in regulation of inflammatory responses, cell
proliferation and apoptosis [118, 119]. The activity of NF-κB
proteins is controlled by cytoplasmic inhibitors of the IκB fam-
ily. Given their important role in immune responses in mature
lymphocytes, it was anticipated that they also are important for
T cell development. This turned out not to be the case. Only
RelB KO mice show defects in the development of thymic
dendritic cells and medullary epithelial cells, but not of thy-
mocytes [120, 121]. All other NF-κB family KO mice display
normal T cell differentiation, although it remains possible that
redundancy exists between family members. Double or even
triple KO mice will have to answer this question.
NF-AT (nuclear factor of activated T cells) was identified
as an inducible TF complex in the IL-2 enhancer by Crabtree
and colleagues [122, 123]. NF-AT consists of a cytoplasmic
component present in resting T cells, which can be any of four
known NF-AT genes (NF-ATp, NF-ATc, NF-AT3, and NF-
AT4). The nuclear component of the complete NF-AT com-
plex is AP1, consisting of dimers of Fos and Jun proteins.
Upon T cell activation, the protein phosphatase Calcineurin is
activated, leading to dephosphorylation and subsequent
nuclear transport of NF-AT.
While NF-ATp-deficient mice have normal thymocyte
development [124], mice with a targeted mutation in the
closely related NF-ATc gene show a defect in T cell differen-
tiation. NF-ATc–/– mice are embryonic lethal, therefore NF-
ATc–/– ES cells were used in a RAG2–/–complementation
assay [125, 126]. The thymus of these RAG2–/–NF-ATc–/–
mice had decreased cellularity and a partial block in the ISP to
DP transition. Thus, although NF-ATc and NF-ATp are
closely related proteins with similar expression patterns, they
play differential roles in early T cell development. Presumably
NF-ATc and NF-ATp bind to sites in the promoters of differ-
ent target genes, or with differential affinity to the same sites.
CREB (cAMP response element binding protein) is a
basic/leucine zipper TF binding to a cAMP response element
(CRE) which is present in promoter/enhancer sequences of
several T cell-specific genes, such as TCRα, TCR Vβ, CD3δ,
and CD8α, but also in many non-T cell genes [127, 128].
After cell stimulation, CREB is phosphorylated on serine 113,
causing its interaction with the coactivator CBP, subsequently
leading to transcriptional activation. CREB dominant-nega-
tive transgenic mice who carry a serine 113 mutation, have
relatively normal T cell development, but increased apoptosis
[129, 130]. This increased apoptosis is due to a G1 cell cycle
arrest [129], that in turn was related to a decreased induction
of AP-1. AP-1 is involved in induction of cytokines required
for cell cycle progression and proliferation.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
During the last 2-3 years, attention of researchers working
on T cell development has focused more on the CD4–CD8–
DN stage than before. The realization that this small subset in
the adult thymus can be subdivided in several subpopulations,
underlying several key developmental checkpoints including
commitment towards the T cell lineage, has spurred a large
number of studies into the biology of these cells. It is clear that
most of the TFs discussed here also play a major role in the
development of the different DN populations. Through the use
of “KO” and conditional KO mice, insight into the role of
these TFs in T cell development has greatly increased. Table 2
summarizes the phenotype of these KO mice.
Clearly it is important to investigate how the different
TFs interact with each other, if they control the same target
genes, or if one factor is target gene of another factor. It is
clear that Notch signaling stimulates T cell development,
while inhibiting B cell developmental choices. In part this
is accomplished by downregulation of E2A genes via
induction of HES-1. How does this repression work? And
how does Notch exert its other effects, that are not mediated
via HES-1, but presumably via other (transcription?) factors?
If GATA-3 might be a target of Ikaros, how is this regulated?
In Drosophila, Notch and wingless signaling converge. Is
there a similar crosstalk between Notch and Wnt signaling
in thymocyte differentiation? And by inference, between
CBF1/HES factors and Tcf/LEF?
For Tcf-1 we have some idea of the signal transduction
routes leading to transcriptional activation (although clearly
not all players are known yet), and indications as to how E2A
is regulated have emerged. But we have no idea of the sig-
naling routes, if any, controlling Ikaros, GATA-3, HEB, or
Sox4. Identification of interacting protein partners is impor-
tant to discover not only how transactivation and repression
by these TFs occur, but also to start elucidation of these sig-
naling routes. These studies are complex, and become even
more complex when one realizes that these factors often have
different splice variants, or are part of a multi-gene family
displaying redundancy in function.
Besides signal transduction routes and interacting part-
ners, the issue of target genes is an important one in order
174 Transcriptional Control of T Lymphocyte Differentiation
 by on November 27, 2006 www.StemCells.comDownloaded from 
to understand the function of these TFs in T cell develop-
ment. Very little is known in this respect, but a great deal of
research effort is devoted to this topic.
Two recent developments in research on lymphoid dif-
ferentiation may help answer the above questions: first, the
application of knowledge from model organisms such as
Drosophila, C. elegans, and zebrafish to T cell develop-
ment. Many molecules and signaling routes are conserved,
allowing some extrapolation of functions and pathways.
For instance, besides the already mentioned Wnt and
Notch pathways, the Hedgehog (Hh) pathway has
recently been shown to regulate differentiation of DN
cells as well [131]. The Hh, wingless/Wnt, and Notch
pathways were all originally discovered in Drosophila. A
second important tool to help our understanding of T cell
development may come from the use of genomics data
via DNA microarrays. With the murine and human
genomes fully sequenced, whole genome approaches will
undoubtedly generate new knowledge of T cell develop-
ment and possibly lead to opportunities for therapeutic
manipulation of T cell function.
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Table 2. TF mutant mice in T cell development
Ikaros Null mice: fetal differentiation, adult maturation blocked
Dominant negative: complete block of lymphoid development
GATA-3 Complete block in T cell development at DN1 stage
Ets-1 Decreased cellularity, NK cell development blocked
Tcf-1 Decreased cellularity, lack of cycling cells, block at DN1, DN2, DN4, and ISP stages. Fetal T cell development normal.
Lef-1 Together with Tcf-1 (V)–/–: complete block at ISP stage.
Sox4 Decreased cellularity, partial block at DN to DP transition
E2A (E12/E47) Somewhat decreased cellularity, partial block at DN1 and ISP stage. Increased SP
HEB Partial block in DN to DP transition
HES-1 Severe block at DN1 stage
NF-ATc Partial block in DN to DP transition
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